Evidence map›Paper›PMID 28173852›Full record

Observational studyBMC cancer2017

Molecular stool testing as an alternative for surveillance colonoscopy: a cross-sectional cohort study.

Meta C J van Lanschot, Beatriz Carvalho, Veerle M H Coupé, Manon van Engeland, Evelien Dekker, Gerrit A Meijer

Registry-linked trialAbstract readComparative StudyMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in BMC cancer, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02715141 (Molecular Stool Testing for Colorectal Cancer Surveillance), which is not on this map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02715141 completednot on this map

Molecular Stool Testing for Colorectal Cancer Surveillance

TypeobservationalSponsorThe Netherlands Cancer InstituteRan2015 to 2020Enrolled3,966ConditionsColorectal CancerArmsCollection of stool sample
3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2022
    Article
  6. Circulating tumour DNA - looking beyond the blood.Nature reviews. Clinical oncology · 2022
    Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Proceedings: Pathways for Successful Translation of New Imaging Agents and Modalities-Phase III Studies.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2019
    Article
  18. Review
  19. Review
  20. Discovery and Validation of Circulating Biomarkers of Colorectal Adenoma by High-Depth Small RNA Sequencing.Clinical cancer research : an official journal of the American Association for Cancer Research · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Meta C J van LanschotDepartment of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, The Netherlands.
Beatriz CarvalhoDepartment of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, The Netherlands.
Veerle M H CoupéDepartment of Epidemiology and Biostatistics, VU medical center, De Boelelaan 1118, 1081 HZ, Amsterdam, The Netherlands.
Manon van EngelandGROW-School for Oncology and Developmental Biology, Maastricht University Medical Center, Universiteitssingel 40 6229 ER, Maastricht, The Netherlands.
Evelien DekkerDepartment of Gastroenterology and Hepatology, Academic Medical Center, Meibergdreef 9 1105 AZ, Amsterdam, The Netherlands.
Gerrit A MeijerDepartment of Pathology, The Netherlands Cancer Institute, Plesmanlaan 121 1066 CX, Amsterdam, The Netherlands. g.meijer@nki.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAs in many other European countries, a nationwide screening program for colorectal cancer (CRC) has recently been introduced in the Netherlands. As a side effect, such a screening program will inherently yield an increase in the demand for surveillance after removal of polyps/adenomas or CRC. Although these patients are at increased risk of metachronous colorectal neoplasia, solid evidence on CRC-related mortality reduction as a result of colonoscopy-based surveillance programs is lacking. Furthermore, colonoscopy-based surveillance leads to high patient burden, high logistic demands and high costs. Therefore, new surveillance strategies are needed. The aim of the present study, named Molecular stool testing for Colorectal CAncer Surveillance (MOCCAS), is to determine the performance characteristics of two established non-invasive tests, i.e., the multitarget stool DNA test Cologuard® and the faecal immunochemical test (FIT) in the detection of CRC and advanced adenomas as an alternative for colonoscopy surveillance.

methodsIn this observational cross-sectional cohort study, subjects aged 50 to 75 years will be approached to collect (whole-) stool samples for molecular testing and a FIT prior to their scheduled surveillance colonoscopy. The results of the tests will allow calculation of test sensitivities and specificities in the context of surveillance. This will provide the required input for the Dutch ASCCA model (Adenoma and Serrated pathway to Colorectal CAncer) to simulate surveillance strategies differing in frequency and duration. The model will allow predictions of lifetime health effects and costs. Multiple centres in the Netherlands will participate in the study that aims to include 4,000 individuals. DISCUSSION: The outcome of this study will inform on the (cost-) effectiveness of stool based molecular testing as an alternative for colonoscopy in the rapidly expanding surveillance population.

trial registrationClinicalTrials.gov ( https://clinicaltrials.gov/ ): NCT02715141 . Retrospectively registered 17 February 2016.

Indexed as

ImmunochemistryResearch DesignAdenomaAgedCohort StudiesColonoscopyColorectal NeoplasmsCross-Sectional StudiesDNA, NeoplasmEarly Detection of CancerFecesHumansMiddle AgedNetherlandsSensitivity and SpecificityDNA, NeoplasmCologuard®Colorectal cancerFITMultitarget stool DNA testingPolypectomySurveillance

Identifiers

PMID28173852
PMCPMC5297018

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.